- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04144569
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
December 25, 2023 updated by: Yongchang Zhang
the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiangyu Zhang, PhD
- Email: 514775505@qq.com
Study Contact Backup
- Name: Yongchang Zhang, MD
- Phone Number: +8613873123436 +8613873123436
- Email: zhangyongchang@csu.edu.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Recruiting
- Hunan Provincal Tumor Hospital
-
Contact:
- Nong Yang, MD
- Phone Number: +86 731 89762323
- Email: yangnong0217@163.com
-
Principal Investigator:
- Nong Yang, MD
-
Contact:
- Yongchang Zhang, MD
- Phone Number: +86 731 89762327
- Email: zhangyongchang@csu.edu.cn
-
Principal Investigator:
- Yongchang Zhang, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Advanced non-small cell lung cancer confirmed by histology or cytology
- HER2 insertion mutation-positive
- Failure with first-line standard chemotherapy
- with measurable lesions.
Exclusion Criteria:
- no measurable tumor lesions
- Patients received PD-1 or Pyrotinib before
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PD-1 Combined With Pyrotinib
PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
|
PD-1 Combined With Pyrotinib
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: Approximately 1 years
|
Progression free survival
|
Approximately 1 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Approximately 1 years
|
To measure the patients's overall response rate
|
Approximately 1 years
|
OS
Time Frame: Approximately 1 years
|
Overall survival
|
Approximately 1 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yongchang Zhang, MD, Hunan Province Tumor Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 30, 2019
Primary Completion (Estimated)
December 30, 2023
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
October 28, 2019
First Submitted That Met QC Criteria
October 28, 2019
First Posted (Actual)
October 30, 2019
Study Record Updates
Last Update Posted (Actual)
December 27, 2023
Last Update Submitted That Met QC Criteria
December 25, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- POETHIS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2 Insertion Mutation Positive Advanced NSCLC
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingHER2-positive Advanced Solid TumorsChina
-
Hangzhou Adcoris Biopharmacy Co., LtdEnrolling by invitationHER2-positive Advanced Solid TumorChina
-
Chinese PLA General HospitalFudan UniversityRecruitingHER2 Positive Advanced Solid TumorsChina
-
Shanghai Pharmaceuticals Holding Co., LtdRecruitingHER2-positive Advanced Solid TumorsChina
-
Samsung Medical CenterCompletedHER2-positive Refractory Advanced CancerKorea, Republic of
-
Krankenhaus NordwestTerminatedHer2/Neu Positive Advanced Solid TumorsGermany
-
AstraZenecaNo longer available
-
Scorpion Therapeutics, Inc.RecruitingNon-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion MutationUnited States, Taiwan
Clinical Trials on PD-1 Combined With Pyrotinib
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHER2-expressing Advanced Solid TumorsChina
-
Sun Yat-sen UniversityRecruitingEsophageal Squamous Cell Carcinoma | Oligometastatic DiseaseChina
-
Peking University Cancer Hospital & InstituteInnovent Biologics (Suzhou) Co. Ltd.CompletedLiver Metastases | Esophageal Squamous Cell Carcinoma | Hepatic Arterial Infusion ChemotherapyChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
The First Affiliated Hospital of Guangdong Pharmaceutical...Guangzhou Anjie Biomedical Technology Co., Ltd.Unknown
-
Shandong Provincial HospitalUnknownRelapsed/Refractory Non-Hodgkin's LymphomaChina
-
Tianjin Medical University Cancer Institute and...RecruitingLocally Advanced Gastric AdenocarcinomaChina
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Guoxin LiNot yet recruiting